Linda L. Kusner – författare

The third edition of this important, gold-standard title outlines a range of significant advances in the study and understanding of myasthenia gravis. The overarching goal of this new edition is identical to the first and second -- to provide the clinician and the scientist with a common resource for understanding the profound achievements in the clinical, translational, and basic sciences of neuromuscular transmission disorders.  In addition to several new authors and an extensive update of all chapters, this third edition includes summaries of pre-clinical research standards for autoimmune MG, along with a broad summary of MG clinical trial performance. The now greater understanding of the clinical presentation of MuSK-related MG and identification of potential new autoantigens, including LRP-4, is discussed. The development of treatment guidelines by groups in Japan, the United Kingdom, Germany, and an international consortium is also outlined. Myasthenia Gravisand Related Disorders, Third Edition, is an invaluable resource for meeting the many and varied needs of clinicians who treat patients with myasthenia gravis.

Myasthenia gravis treatment has seen remarkable progress, with FDA approval of a first-in-class drug targeting autoimmunity. Additionally, more than 20 therapies are currently in development, ranging from pre-clinical stages to Phase 3 trials.This new and expanded edition explores these new therapies and other new developments in MG. The book retains its comprehensive review of MG, covering clinical presentation, laboratory and electrophysiological diagnosis, and treatment. These chapters offer neurologists and neuromuscular experts the latest insights into state-of-the-art patient care. The text then delves into focused chapters on epidemiology, genetics, and cancer-associated MG, broadening the appeal to scientists exploring the autoimmune drivers linked to tumors and the genetic underpinnings of MG pathophysiology.Chapters on related disorders are included due to their clinical and pathological similarities to MG. These sections provide valuable insights into antibody-mediated diseases that mirror MG in their clinical manifestations. Finally, the book concludes with chapters on clinical trial design, biomarker development, and the psychological impact of MG on patients. These chapters are essential not only for academic clinical investigators but also for professionals in the pharmaceutical industry, from research scientists to clinical trial developers.Myasthenia Gravis and Related Disorders, 4th Edition is the definitive resource for researchers and clinicians in this rapidly evolving field.

The third edition of this important, gold-standard title outlines a range of significant advances in the study and understanding of myasthenia gravis. The overarching goal of this new edition is identical to the first and second -- to provide the clinician and the scientist with a common resource for understanding the profound achievements in the clinical, translational, and basic sciences of neuromuscular transmission disorders.  In addition to several new authors and an extensive update of all chapters, this third edition includes summaries of pre-clinical research standards for autoimmune MG, along with a broad summary of MG clinical trial performance. The now greater understanding of the clinical presentation of MuSK-related MG and identification of potential new autoantigens, including LRP-4, is discussed. The development of treatment guidelines by groups in Japan, the United Kingdom, Germany, and an international consortium is also outlined. Myasthenia Gravisand Related Disorders, Third Edition, is an invaluable resource for meeting the many and varied needs of clinicians who treat patients with myasthenia gravis.